Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?

about

[The 308 nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases].

P2860

Q49331846-FC05F53E-A2F0-4CAF-A205-F9905BE8CF45

P2860

Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?

Item

http://www.wikidata.org/entity/Q36272552

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@ast

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@en

type

Item

label

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@ast

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@en

prefLabel

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@ast

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@en

P1476

Does imiquimod pretreatment op ...... therapy in psoriasis patients?

@en

P2093

Andrew Young

http://www.w3.org/2001/XMLSchema#string

David C Soler

http://www.w3.org/2001/XMLSchema#string

Joselin D Tacastacas

http://www.w3.org/2001/XMLSchema#string

Kevin D Cooper

http://www.w3.org/2001/XMLSchema#string

Kord Honda

http://www.w3.org/2001/XMLSchema#string

Patricia Oyetakin-White

http://www.w3.org/2001/XMLSchema#string

Sarah Groft

http://www.w3.org/2001/XMLSchema#string

P2860

Imiquimod applied topically: a novel immune response modifier and new class of drug

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

Medium-dose 308-nm excimer laser for the treatment of psoriasis.

Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques

Diagnosis and classification of psoriasis.

Single administration of lesion-limited high-dose (TURBO) ultraviolet B using the excimer laser: clinical clearing in association with apoptosis of epidermal and dermal T cell subsets in psoriasis.

Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation.

Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.

TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis.

Therapeutic targeting of Toll-like receptors: a review of Toll-like receptors and their signaling pathways in psoriasis.

P304

193-202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PHPP.12299

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas S. McCormick

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28168735

http://www.w3.org/2001/XMLSchema#string

P921

excimer laser

P932

5505796

http://www.w3.org/2001/XMLSchema#string

Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?

about

P2860

P2860

Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932